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ABSTRACT
Objective Although Th17 cells have been increasingly
recognised as an important effector in various autoimmune
diseases, their function in the pathogenesis of Sjögren’s
syndrome (SS) remains largely uncharacterised. This study
aims to determine the role of Th17 cells in the
development of experimental SS (ESS).
Methods The ESS was induced in wildtype and IL-17A
knockout (IL-17 KO) C57BL/6 mice immunised with
salivary glands (SG) proteins. Phenotypic analysis of
immune cells in the draining cervical lymph nodes (CLN)
and SG was performed by ﬂow cytometry and
immunoﬂuorescence microscopy. To determine the role of
Th17 cells in ESS, immunised IL-17 KO mice were
adoptively transferred with in vitro-generated Th17 cells
and monitored for SS development. The salivary ﬂow rate
was measured, whereas inﬂammatory inﬁltration and
tissue destruction in SG were assessed by histopathology.
Results SG protein-immunised mice developed overt SS
symptoms with increased Th17 cells detected in CLN and
within lymphocytic foci in inﬂamed SG. Notably,
immunised IL-17 KO mice were completely resistant for SS
induction, showing no evidence of disease symptoms and
histopathological changes in SG. Adoptive transfer of
Th17 cells rapidly induced the onset of ESS in immunised
IL-17 KO mice with markedly reduced saliva secretion,
elevated autoantibody production and pronounced
inﬂammation and tissue damage in SG.
Conclusions Our ﬁndings have deﬁned a critical role of
Th17 cells in the pathogenesis of ESS. Further studies may
validate Th17 cell as a potential target for treating SS.Q10
INTRODUCTION
As a systemic autoimmune disease, primary
Sjögren’s syndrome (SS) is characterised by progres-
sive inﬂammation and tissue damage of salivary
glands (SG) and lacrimal glands, leading to dry-
mouth and dry-eye symptoms as a result of reduced
secretion of saliva and tears.1–3 Histopathologically,
SS is mainly featured with extensive lymphocytic
inﬁltration and glandular destruction in exocrine
glands.4 Early studies have depicted the swollen
glands accompanied with enlarged cervical lymph
nodes (CLN) in SS patients.5 Moreover, reduced
cervical lymphadenopathy and glandular swelling
were observed in SS patients after corticosteroid
treatment,6 indicating the involvement of immune
responses in CLN during the disease pathogenesis.
Inﬂammatory inﬁltrates in SG consist of macro-
phages, dendritic cells (DCs), T cells and B cells
with a predominant presence of CD4 Q7T cells.7–9
Although the aetiology of SS still remains unclear,
studies using various animal models have indicated
a pivotal role of T cell-mediated autoimmune
inﬂammation in SS pathogenesis.10 11 Accumulated
data have also shown a signiﬁcant contribution of
dysregulated cytokine network to the development
of SS.12 Although studies on NOD/Ltj and C57BL/
6.NOD-Aec1Aec2 mice with SS-like disease have
clearly illustrated the important implication of Th1
and Th2 cytokines in the pathogenesis of SS,13 14
a pivotal role of IL-17 has been increasingly recog-
nised in the disease process. In patients with SS,
increased levels of circulating IL-17 have been
observed, whereas IL-17-expressing cells are identi-
ﬁed as a dominant population within inﬂammatory
lesions in SG.15 Recent studies by Nguyen et al16
have elegantly demonstrated an important function
of IL-17 during SS induction in SS-non-susceptible
C57BL/6 mice.
As a key effector T cell subset distinct from the
Th1 and Th2 CD4 T lineages, IL-17-producing
CD4 T (Th17) cells have been identiﬁed to play an
important role in immune response and auto-
immune pathogenesis.17 18 Recent studies including
our recent ﬁndings have highlighted a pathogenic
role of Th17 cells in animal models for rheumatoid
arthritis and systemic lupus erythematosus.19 20
Notably, the presence of Th17 cells in SG of
patients with SS is associated with focus
scores.15 21 Although lines of evidence indicate that
overexpression of IL-17 exacerbates the disease
progression of SS, it remains unclear whether Th17
cells play a pivotal role in the pathogenesis of SS.22
In this study, we ﬁrst characterised the kinetic
changes of Th17 cells in draining CLN and within
lymphocytic inﬁltrates in SG of mice with experi-
mental SS (ESS). To further deﬁne the function of
Th17 cells in ESS, adoptive transfer of Th17 cells
was performed in SG protein-immunised IL-17
knockout (KO) mice. Together, our ﬁndings identi-
ﬁed a critical role of Th17 cells in the development
of ESS.
MATERIALS AND METHODS
Induction of SS in mice
The ESS mouse model was induced in 8-week-old
female wildtype (WT) or IL-17 KO C57BL/6 mice
(kindly provided by Dr Yoichiro Iwakura from
University of Tokyo) by immunisation with SG pro-
teins using our previously described protocol with
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modiﬁcations.23 For SG protein preparation, the bilateral SG
from naïve WT mice was collected for homogenisation in phos-
phate buffered saline and centrifuged at 12 000×g for 5 min at
4°C. The supernatant was collected with protein concentration
determined by the bicinchoninic acid assay (Sigma-Aldrich) and
emulsiﬁed in an equal volume of Freund’s complete adjuvant
(Sigma-Aldrich) to a concentration of 2 mg/mL. For SS induc-
tion, each mouse received subcutaneous multiinjections on the
back with 0.1 mL of the emulsion on days 0 and 7, respectively.
On day 14, the booster injection was carried out with a dose of
1 mg/mL SG proteins emulsiﬁed in Freund’s incomplete adju-
vant (Sigma-Aldrich). Mice immunised with either proteins
extracted from pancreas or adjuvant alone served as controls.
NOD/shiLtj mice were purchased from the Jackson Laboratory
(Bar Harbor, ME). All animal studies were approved by the
Committee on the Use of Live Animals in Teaching and
Research of the University of Hong Kong.
Saliva and blood collection
After the animals were anesthetised, saliva secretion was
induced by intraperitoneal injection of pilocarpine (Sigma-
Aldrich) at a dose of 5 mg/kg body weight.23 Stimulated whole
saliva was gravimetrically collected using a 20 μL sized pipet tip
from the oral cavity for 15 min at room temperature. Blood
samples were collected for serum preparation.
Phenotypic analysis of SG-inﬁltrating leucocytes
SG-inﬁltrating leucocytes were harvested as previously
described.24 To avoid contamination of sequestered leucocytes
with non-inﬂammatory circulating cells, extensive intracardial
perfusion of ESS mice prior to organ extraction was performed.
Sorting-puriﬁed CD4 T cells were subsequently examined by
ELISPOTassay.
Detection of serum autoantibodies
Serum samples from WT and IL-17 KO mice were analysed for
autoantibodies against SG proteins, M3 muscarinic receptor
(M3R) and antinuclear antibodies (ANA). Peptides encoding
murine M3R extracellular domains (VLVNTFCDSCIPKTYW
NLGY)25 or control peptides (SGSGSGSGSGSGSGSGSGSG)
were synthesised chemically by a solid-phase approach and puri-
ﬁed by high performance liquid chromatography (SBS Genetec
Co., Ltd). Serum antibodies were measured by a standard ELISA
assay.19
Histological assessment and immunoﬂuorescence
microscopy
Mouse SG tissues were prepared for sectioning with haematoxy-
lin and eosin (H&E) staining. Awidely used scoring system based
on the size and the degree of lymphoid organisation of the inﬁl-
trates was adopted to assess the severity of tissue damage.26
For immunoﬂuorescent microscopy, frozen sections were
stained with monoclonal rat antimouse anti-CD4 (clone RM4-5),
biotinylated rat antimouse IL-17 (clone TC11-18H10.1) and
FITC-streptavidin (BioLegend) while nuclei were counterstained
with Hoechst 33258 (CalBioChem). Rat IgG antibody was used
for control staining.
Detection of apoptotic cells in situ
Terminal uridine nick-end labelling (TUNEL) assay was per-
formed as previously described.27 Frozen sections were analysed
with a confocal laser scanning microscope (LSM 710, Carl
Zeiss).
Flow cytometric analysis
Surface markers were identiﬁed with the following monoclonal
antibodies (BioLegend): anti-CD4 (clone GK1.5), anti-CD3
(clone 145-2C11), anti-CD8 (clone 53-6.7), anti-CD19 (clone
6D5), anti-CD45 (clone 30-F11), anti-GL-7 and anti-Fas (clone
15A7). The intracellular staining for IFN-γ and IL-17 was per-
formed as previously described.28 Stained cells were analysed
with a FACS Calibur ﬂow cytometer (BD Biosciences).
Adoptive transfer of Th17 cells
Mouse splenic CD4 T cells were cultured for Th17 differenti-
ation as previously described.28 Puriﬁcation of Th17 cells was
performed using a mouse IL-17 secretion and enrichment assay
kit (Miltenyi Biotec). Puriﬁed Th17 cells (1×106) were intraven-
ously transferred into IL-17 KO mice on the day of boosting
immunisation while the control group was transferred with
1×106 CD4 T cells from IL-17 KO mice.
Data analysis and statistics
Results are expressed as mean±SD. Data were analysed using an
unpaired Student t test to determine the difference between
groups using SPSS V16.0 (*p<0.05, **p<0.01 and ***p<0.001).
RESULTS
Enhanced Th17 cell response during the development of
ESS in mice
Upon immunisation with SG proteins, C57BL/6 mice developed
a full disease proﬁle of ESS, including reduced saliva secretion,
elevated serum autoantibody production and tissue destruction
with lymphocytic inﬁltration in submandibular gland (ﬁgure 1).
To further examine the antigen speciﬁcity in ESS induction,
mice were also immunised with pancreatic proteins (see online
supplementary figure S1). We found that SG protein-immunised
mice started to exhibit a signiﬁcant reduction in salivary ﬂow
rate on day 7 postimmunisation while control groups immu-
nised with either adjuvant alone or pancreatic proteins did not
develop any sign of disease symptoms (ﬁgure 1A; see online
supplementary figure S1A). Moreover, levels of autoantibodies
against total SG antigens, M3R and ANA were signiﬁcantly ele-
vated in the sera of SG protein-immunised mice (ﬁgure 1B,C;
see online supplementary figure S1B). Notably, SG protein-
immunised mice displayed substantially enlarged SG and CLN
during ESS development, whereas other secretory glands such
as pancreas remained unaffected (ﬁgure 1D and data not
shown). Flow cytometric analysis revealed both signiﬁcantly
increased frequency and total number of Th17 cells in CLN of
SG protein-immunised mice compared with controls (ﬁgure
1E). In addition, the total number of CD8 T cells and γδ-T cells
was found slightly increased in the CLN of ESS mice (ﬁgure
1F). Notably, no obvious immune responses, including IFN-γ
and IL-17 production, were detected in mice immunised with
pancreatic proteins (see online supplementary figure S1C,D).
To ascertain the presence of Th17 cells among lymphocytic
inﬁltration in SG, we performed histological analysis on the
tissue sections of submandibular gland from ESS mice and con-
trols. Large lymphocytic inﬁltrates become prominent in the
submandibular gland of ESS mice 5 weeks postimmunisation,
with multiple lymphocytic foci and extensive acinar destruction
readily detected at 30 weeks postimmunisation (ﬁgure 2A). In
contrast, leucocyte inﬁltration and tissue destruction were not
detected in the SG of control animals immunised with either
adjuvant or pancreatic proteins (see online supplementary figure
S1E). Using a previously described scoring system,26 we
2 Lin X, et al. Ann Rheum Dis 2014;0:1–9. doi:10.1136/annrheumdis-2013-204584
Basic and translational research
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
quantiﬁed the number of inﬁltrated lymphocytes and found sig-
niﬁcantly increased histological scores in submandibular gland
of mice with ESS (ﬁgure 2B). Flow cytometric analysis identiﬁed
CD4 T cells as the major cell subset among inﬁltrated CD45 leu-
cocytes in SG at early stage, followed by gradually increased
inﬁltration of B cells (ﬁgure 2C,D). IL-17-producing CD4 T
cells were detected as the major source of IL-17 in the inﬁltrates
by immunoﬂuorescence microscopy (ﬁgure 2E), which was
further conﬁrmed by ELISOPTassay (ﬁgure 2F).
Enhanced Th17 responses occur in CLN and SG during
ESS development
Next, we examined the kinetic changes of Th1 and Th17
responses in the draining CLN at various time intervals during
ESS induction. Th17 cells were signiﬁcantly increased 7 days
prior to an enhanced Th1 response in CLN of ESS mice, with a
peaked Th17 response detected on day 17 post ﬁrst immunisa-
tion (ﬁgure 3). During ESS development, the enhanced Th17
response in the CLN rapidly diminished from day 24 onward
while a persistent elevation of Th1 response was maintained till
30 weeks post ﬁrst immunisation. Notably, a similar pattern of
Th17/Th1 shift was also observed in CLN of NOD mice, a
mouse model with spontaneous SS-like autoimmune exocrino-
pathy (see online supplementary figure S2). Together, these
results identify an initially enhanced Th17 response prior to
Th1 response during ESS development.
We further examined the kinetic changes of SG-inﬁltrating Th17
cells during ESS progression. Flow cytometric analysis revealed that
both frequencies and total number of Th17 cells were persistently
increased in SG up to 30 weeks postimmunisation (ﬁgure 3B).
Figure 1 Q9SG protein-immunised mice develop ESS with enhanced Th17 cell response. (A) The saliva ﬂow rates were measured in SG
protein-immunised mice for ESS induction (ESS) and control mice (Ctrl) immunised with adjuvant (n=19 for each group). Signiﬁcant reduction in
salivary secretion was detected in ESS mice on day 7 postimmunisation. (B, C) Autoantibodies against SG antigens (B), M3 muscarinic receptor
(M3R, black column) and antinuclear antibodies (ANA, grey column) (C) were detected in the serum samples from ESS mice and controls 35 days
post ﬁrst immunisation by ELISA. (D) Representative micrographs showing the sizes of salivary glands and cervical lymph nodes (CLN) from ESS mice
and controls (bar=1 cm). (E) Phenotypic analysis of T cells in CLN by ﬂow cytometry at 35 days post ﬁrst immunisation. Gated on CD4 T cells,
intracellular expression of IFN-γ and IL-17 was detected by ﬂow cytometry. (F), Total numbers of CD4 T cells, Th1 and Th17 cells in CLN were
enumerated in ESS mice and adjuvant-immunised controls (n=19 for each group). Values are derived from three separate experiments (mean±SD;
*p<0.05; **p<0.01; ***p<0.001). ESS, experimental Sjögren’s syndrome; SG, salivary glands.
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A critical role of IL-17 in the development of ESS
To deﬁne the function of IL-17, the signature cytokine produced
by Th17 cells, in the pathogenesis of ESS, we immunised IL-17
KO mice with SG proteins for ESS induction. Remarkably, the
immunised IL-17 KO mice exhibited no clinical symptoms and
histological changes in SG up to 24 weeks of age. As shown in
ﬁgure 4A, the saliva ﬂow rate remained unaffected in immunised
IL-17 KO mice while immunised WT mice showed a signiﬁcant
reduction. Moreover, there were no signs of cervical lymphaden-
opathy and tissue destruction in the SG of immunised IL-17 KO
mice (ﬁgure 4B–D). As expected, ﬂow cytometric analysis detected
no Th17 cells both in CLN and SG of IL-17 KO mice while WT
mice showed signiﬁcantly increased Th17 response upon ESS
induction (ﬁgure 4E and data not shown). Furthermore, detailed
analysis of various types of IL-17-producing leucocytes conﬁrmed
that Th17 cells were the predominant IL-17-producing cell subset
in the LN of ESS mice (ﬁgure 4G).
Adoptive transfer of Th17 cells drives ESS development
in IL-17 KO mice
To further deﬁne the role of Th17 cells in the pathogenesis of
ESS, we examined whether adoptive transfer of Th17 cells
Figure 2 Inﬁltrated Th17 cells in the submandibular gland of ESS mice. (A) Histological evaluation of glandular destruction in mice immunised
with SG proteins for ESS induction (ESS) and controls (Ctrl) was performed on tissue sections of submandibular glands with H&E staining (n=15 for
each group; bar=50 μm). (B) Inﬁltrated lymphocytes in the acinar tissue were assessed for histological scores. (C) Phenotypic analysis of inﬁltrating
CD45 cells in the submandibular gland collected from ESS mice at 5 and 30 weeks postimmunisation. Frequencies of CD4 T cells and CD19 B cells
are indicated in the representative ﬂow proﬁles. (D) Cell counts of SG-inﬁltrating CD4, CD8 T cells and CD19 B cells at 5 and 30 weeks
postimmunisation (mean±SD; ***p<0.001). (E) IL-17-producing CD4 Th17 cells (arrows) in the submandibular gland of ESS mice 30 weeks
postimmunisation were detected (bar=20 μm). (F) Inﬁltrated CD4 T cells were sorting-puriﬁed and examined for IFN-γ and IL-17 production at 5 and
30 weeks postimmunisation by ELISPOT assay. Bars are the average number of spot forming cells per 5000 cells (mean±SD; *p<0.05). ESS,
experimental Sjögren’s syndrome; SG, salivary glands.
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Figure 3 Kinetic changes of Th17 responses in CLN and SG during ESS development. (A) Frequencies of IFN-γ and IL-17-producing Th1 and Th17
cells in the cervical lymph nodes (CLN) of mice immunised for ESS induction were examined by ﬂow cytometry analysis on days 0, 3, 10, 17, 24 and
30 weeks post ﬁrst immunisation. Total cell numbers of Th1 and Th17 cells in CLN of ESS mice or control mice immunised with adjuvant alone on
various time intervals post ﬁrst immunisation were enumerated and compared with their respective numbers on day 0. (B) SG-inﬁltrating Th17 cells
were analysed by ﬂow cytometry at 5, 10, 15, 25 and 30 weeks post ﬁrst immunisation. Total cell numbers were enumerated and compared with
their respective numbers on 5 weeks. Data are derived from three separate experiments (mean±SD; n=10; *p<0.05; **p<0.01; ***p<0.001). ESS,
experimental Sjögren’s syndrome; SG, salivary glands.
Figure 4 IL-17 KO mice are resistant for ESS induction. (A) SG protein-immunised IL-17 KO mice exhibited normal salivary secretion while
signiﬁcantly decreased saliva ﬂow rates were observed in immunised wildtype (WT) mice. (B) Representative micrographs showing glandular
destruction in the SG of WT mice with ESS; normal histology was observed in the SG of immunised IL-17 KO mice at 24 weeks of age (n=15 for
each group). (C) Acinar tissues in SG were assessed for histological scores. (D) Representative micrographs show the sizes of salivary gland and CLN
of IL-17 KO mice and WT mice upon ESS induction (bar=1 cm). (E, F) Both frequencies and total numbers of Th1 and Th17 cells in the CLN of IL-17
KO mice and WT controls with ESS were analysed by ﬂow cytometry. (G) Total numbers of various IL-17-producing cell populations in CLN of WT
mice with ESS were enumerated by ﬂow cytometry (n=10 for each group). Values are derived from three separate experiments (mean±SD; **p<0.01
and ***p<0.001). CLN, cervical lymph nodes ESS, experimental Sjögren’s syndrome; IL-17 KO, IL-17A knockout; SG, salivary glands.
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could promote the development of ESS in SG-protein immu-
nised IL-17 KO mice. First, naïve CD4 T cells isolated from the
spleen of WT mice were cultured under a Th17-polarising con-
dition, followed by puriﬁcation of IL-17-producing Th17 cells
using a cytokine capture assay (ﬁgure 5A).28 One week after
adoptive transfer of puriﬁed Th17 cells, immunised IL-17 KO
mice began to show markedly reduced saliva rates, displaying a
similar disease proﬁle with decreased saliva secretion as WT ESS
controls (ﬁgure 5B). Histological examination detected exten-
sive acinar apoptosis and submandibular gland destruction with
periductal foci of CD4T cell inﬁltrates in Th17 cell-transferred
IL-17 KO mice (ﬁgure 5C). Notably, control groups of IL-17
KO mice transferred with or without CD4 T cells from IL-17
KO mice did not show any signiﬁcant reduction in salivary
secretion with normal glandular structure observed in SG. Thus,
these ﬁndings reveal a critical role of Th17 cells in driving the
development of SS in mice.
Adoptive transfer of Th17 cells enhances Th1 and B cell
responses in IL-17 KO mice
In Th17 cell-transferred IL-17 KO mice, we found signiﬁcantly
increased frequencies and total numbers of Th1 cells and GL-7+
Fas+ germinal centre (GC) B cells in the enlarged CLN by ﬂow
cytometric analysis (ﬁgure 6A–D). Moreover, immunoﬂuores-
cence microscopy conﬁrmed both increased numbers and sizes
of GCs in the CLN of Th17 cell-transferred IL-17 KO mice
(ﬁgure 6E). Elevated levels of serum autoantibodies against total
SG antigens and M3R were detected in Th17 cell-transferred
IL-17 KO mice but not in IL-17 KO mice transferred with CD4
T cells (ﬁgure 6F). Remarkably, similar levels of elevated serum
autoantibodies were detected between Th17 cell-transferred
IL-17 KO mice and WT ESS controls. Furthermore, we
observed pronounced inﬁltration of CD4 T cells in the SG of
Th17 cell-transferred IL-17KO mice, among which transferred
Th17 cells were also detected (ﬁgure 6G). These results suggest
that adoptive transfer of Th17 cells may drive the development
of ESS via promoting Th1 and B cell responses.
DISCUSSION
In this study, we have revealed an enhanced Th17 response in
draining CLN and prominent inﬁltration of Th17 cells in SG
during ESS development. Although IL-17-deﬁcient mice are
completely resistant for ESS induction, adoptive transfer of
Th17 cells can drive the development of ESS in IL-17 KO mice
as featured by reduced salivary secretion and tissue destruction
in the SG. Together, these results have demonstrated a critical
role of Th17 cells in the pathogenesis of ESS.
Up to date, many mouse models with SS-like disease have
been used for investigating SS pathophysiology. SG proteins
such as laminin and exosomes have been characterised as auto-
antigens in initiating SS while most SS patients exhibit signiﬁ-
cantly increased autoantibodies against M3R.29–32 In this study,
we successfully induced a full proﬁle of SS-like disease with
characteristic autoantibody production in SG protein-immunised
C57BL/6 mice, which allow us to study immune dysregulations
during ESS development in a normal mouse strain without
genetic susceptibility. Notably, our observations that pancreatic
protein-immunised mice did not exhibit any detectable immune
responses and pathological changes in SG further conﬁrm the
antigen speciﬁcity against SG in ESS model. Earlier studies have
suggested Th1 cytokine-mediated inﬂammatory responses in SS
patients,33–36 but increasing evidence indicates the involvement
of IL-17 in autoimmune inﬂammation during the pathogenesis
of SS.37 Here, we reveal a signiﬁcantly enhanced Th17 response
occurring 7 days prior to the predominant Th1 response during
ESS induction. Notably, similar kinetic changes of Th17
Figure 5 Adoptive transfer of Th17 cells induces ESS development in immunised IL-17 KO mice. (A) Puriﬁed CD4 T cells from wildtype (WT) mice
were cultured in the Th17 cell polarisation media for 4 days. Th17 cells enriched by cytokine capture assay were further examined for purity by ﬂow
cytometry. (B) Changes in saliva ﬂow rates were measured in SG protein-immunised IL-17 KO mice with adoptively transferred either Th17 cells from
WT mice or CD4 T cells from IL-17 KO mice compared with control group immunised with adjuvant alone (n=14 for each group). Values (mean±SD)
are derived from four separate experiments (**p<0.01). (C) The upper panel micrographs show histological assessment of tissue destruction in SG of
IL-17 KO mice 3 weeks after transferred with either Th17 cells or control CD4 T cells (bars=10 μm). Micrographs in the middle panel show inﬁltrated
CD4 T cells in the SG of Th17 cell-transferred mice, whereas the lower panel indicates the detection of apoptotic cells in SG by TUNEL staining. ESS,
experimental Sjögren’s syndrome; IL-17 KO, IL-17A knockout; TUNEL, terminal uridine nick-end labelling; SG, salivary glands.
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response followed by increased Th1 response were also
observed in NOD mice with SS-like disease (see online supple-
mentary figure S2). Moreover, adoptive transfer of Th17 cells
resulted in markedly enhanced Th1 response in vivo, which sug-
gests a pivotal role of Th17 cells in initiating inﬂammatory reac-
tions and driving T cell-mediated disease pathologies during the
development of ESS. Although the mechanisms involved in
Th17/Th1 shift remain currently unclear, recent studies have
indicated a role of IL-17-stimulated DCs in driving Th1 cell
polarisation under autoimmune conditions.38
In patients with SS, the predominant IL-17 expression in
CD4 T cells within lymphocytic inﬁltrates has been detected in
the SG.15 IL-17-producing cells are also found within the
lymphocytic foci in the SG of C57BL/6.NOD-Aec1Aec2 mice
with SS-like disease.39 However, the available data only sug-
gested the possible involvement of Th17 cells in the disease pro-
gression but did not demonstrate Th17 cells as the major
effector in the pathogenesis of SS. Here, we provide strong
evidence that adoptive transfer of Th17 cells can effectively
trigger the onset and progression of SS in IL-17 KO mice.
Moreover, adoptive transfer of CD4 T cells from IL-17-deﬁcient
mice failed to induce the development of ESS in IL-17 KO
mice, which further highlight a critical function of Th17 cell-
derived IL-17 in driving the disease pathologies. Since increased
peripheral Th17 cells in SS patients have been recently
reported,15 40 it remains to be investigated whether peripheral
Th17 cells could serve as a biomarker for disease activity.
During ESS development, we have detected markedly increased
serum antibodies against SG antigens, M3R and ANA in IL-17 KO
mice 2 weeks after Th17 cells transfer (ﬁgure 6), indicating an aug-
mented antibody response mediated by Th17 cells in vivo. In add-
ition, GC B cells in CLN are markedly increased in Th17
cell-transferred IL-17 KO mice. Thus, these data clearly indicate
that adoptive transfer of Th17 cells effectively drives B cell activa-
tion and maturation, resulting in augmented antibody response
in vivo. Collectively, our results are consistent with recent ﬁndings
Figure 6 Enhanced Th1 and B cell
response in IL-17 KO mice transferred
with Th17 cells. (A) Representative
micrograph shows the sizes of SG and
CLN from wildtype (WT) naïve mice
and SG protein-immunised IL-17 KO
mice transferred with either CD4 T
cells from IL-17 KO mice or Th17 cells
from WT mice (bar=1 cm). (B, C) Flow
cytometric analysis of Th1 cells (B) and
germinal centre (GC) B cells (C) in the
CLN of mice. (D) The total number of
GC B and Th1 cells in CLN were
enumerated for comparison among
various groups (mean±SD;
***p<0.001). (E) Examination of GCs
(PNA+ IgD−) in CLN in immunised
IL-17 KO mice 3 weeks after adoptive
transfer of control CD4 T cells and
Th17 cells, respectively, by confocal
microscopy (bar=50 μm). (F) Elevated
levels of serum antibodies against SG
antigens and M3R were detected by
ELISA in IL-17 KO mice transferred
with Th17 cells for 3 weeks, showing
similar titres as those detected in WT
mice with ESS. Values (mean±SD) are
derived from four separate experiments
(**p<0.01 and ***p<0.001). (G)
IL-17-producing CD4 Th17 cells
(arrows) in the submandibular gland of
immunised IL-17 KO mice 15 weeks
after Th17 cells transfer were detected
(bar=20 μm). CLN, cervical lymph
nodes; ESS, experimental Sjögren’s
syndrome; IL-17 KO, IL-17A knockout;
SG, salivary glands.
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that Th17 cells act as an effective B cell helper in promoting B cell
activation and autoantibody-induced arthritis.41
Recent studies have identiﬁed many proinﬂammatory mole-
cules involved in promoting IL-17-mediated inﬂammatory cas-
cades.12 42 B cell-activating factor (BAFF) transgenic mice
develop SS-like disease with inﬁltration of large amounts of
marginal zone B cells found in SG along with increased BAFF
expression.43 Several studies have characterised the aberrant ele-
vation of BAFF in the SG of patients with SS.44–46 We recently
showed that BAFF and leptin exacerbate collagen-induced arth-
ritis via promoting IL-17 response, suggesting a key effector
function of IL-17 in autoimmune inﬂammation.19 47 Although
SS is characterised by extensive lymphocytic inﬁltration with
predominant presence of CD4 T cells, B cells and macrophages
are also present in the inﬂammatory lesion in SG. Interestingly,
SG epithelial cells in SS patients have been found to produce
BAFF under inﬂammatory conditions.48 Furthermore, activated
DCs with increased TNF-α production may contribute to
disease onset, resulting in salivary dysfunction before the rise of
pathogenic autoantibodies and evident lymphocytic inﬁltration
in SG.49 50 Thus, further studies are needed to delineate the
cytokine network dysregulations and immune cell dysfunctions
in SS, which will provide new insights into understanding the
pathophysiology of SS.
In summary, this study identiﬁes a central role played by
Th17 cells in driving the pathogenesis of ESS in mice. Future
studies may validate the targeting of Th17 cells as a therapeutic
strategy for the treatment of SS.
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